Shadow Robot Company Launches Robotics Consulting and Advisory Services

The Shadow Robot Company, the UK’s pioneering robotics company best-known for its Dextrous Hand series, today announced the launch of its Robotics Consultancy Service.

The Shadow Robot Company, a London-based robotics company that designs and manufactures state-of-the-art anthropomorphic robot hands and systems, is launching its robotics consultancy service to help companies innovate by integrating robotic hand technology into their products and processes.

The robotics consultancy service will provide companies with expert advice and guidance on how to design and use robotic hand technology to enhance their performance, efficiency, and competitiveness. The service will also offer customised solutions and support for specific challenges and needs, thanks to its inhouse engineering and production facilities and teams.

  • The range of services include:
    Technical expertise – advising on all aspects of robotic hand design, development, and deployment, including feasibility studies, prototyping, testing and validation.
  • System integration – integrating robotic hands into existing systems through hardware and software solutions, as well as training and support.
  • Application development: developing applications for robotic hands into new products and processes or improving existing ones.

The Shadow Robot Company’s Director, Rich Walker, said: “We are excited to launch our robotics consultancy service and share our expertise and knowledge with other companies who want to innovate with robotic hand technology. We’ve been pleased to see the number of companies developing their own robot hands, and we want to offer the expertise of the ‘best in class’ robot hand developers to the wider community.

“We believe that robotic hand technologies have enormous potential to transform various industries and sectors, and we are eager to help our clients achieve their goals and visions,” he added.

The Shadow Robot Company has more than 20 years of experience in designing and developing robotic systems for research and industry. The company has worked with clients such as NASA, ESA, OpenAI, Google Brain, MIT, University of Oxford, University of Cambridge, and many others.

The company has also won several awards for its innovation and excellence in robotics, such as the Queen’s Award for Enterprise for Innovation in 2019, the AIconics Award for Best Innovation in AI Hardware in 2019 and the E&T Innovation Awards for Excellence in R&D, Intelligent Systems and Tech for Good in 2020.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.